ribavirin
| Per policy, these hazardous drugs have special waste requirements. | |
|---|---|
| Generic (Brand) | Waste Requirements |
| ribavirin (Moderiba) | Hazardous Waste ⇒ BLACK BUCKET |
| USP <800> Hazardous Drugs | ||||||
|---|---|---|---|---|---|---|
| Per Policy, these drugs have special handling requirements (any drug with an "AOR" is exempt from these requirements under normal circumstances). | ||||||
| generic (Brand) Route | Relative Risk Level | AOR? | NIOSH 2024 Table | MSHI?↑ | Warnings | |
| ribavirin (Moderiba) PO | Low | N/A | 2B↑ | |||
| NIOSH Supplemental information (2016): Teratogenic and embryotoxic effects in several laboratory studies; contraindicated in women who are pregnant and in the male partners of women who are pregnant FDA Pregancy Category X: Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits; | ||||||
| Pediatric Pharmacy Association 2025 KIDs List of Key Potentially Inappropriate Drugs in Pediatrics | |
|---|---|
| Medication: | ribavirin (oral inhalation) (Virazole) |
| Key Potentially Inappropriate Drugs in Pediatrics (KIDs) List: Second Edition (Table 1) | |
| Drug | ribavirin (oral inhalation) |
| Risk/Rationale | Sudden respiratory deterioration |
| Recommendation | Caution in younger than 2 yr |
| Quality of evidence: Low, Strength of Recommendation: Strong | |